Modality
Gene Editing
MOA
RAS(ON)i
Target
SHP2
Pathway
Autophagy
Ewing SarcomaLGS
Development Pipeline
Preclinical
Nov 2020
→ Aug 2030
PreclinicalCurrent
NCT05560121
2,891 pts·Ewing Sarcoma
2020-11→2030-08·Active
NCT04779591
2,675 pts·LGS
2025-01→2026-07·Recruiting
5,566 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-093mo awayInterim· LGS
2030-08-184.4y awayInterim· Ewing Sarcoma
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Active
Preclinical
Recruit…
Catalysts
Interim
2026-07-09 · 3mo away
LGS
Interim
2030-08-18 · 4.4y away
Ewing Sarcoma
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05560121 | Preclinical | Ewing Sarcoma | Active | 2891 | 6MWD |
| NCT04779591 | Preclinical | LGS | Recruiting | 2675 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |